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http://dx.doi.org/10.1016/j.ccr.2014.01.009SUMMARYMuscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely variable clinical
outcomes and responses to conventional chemotherapy. We discovered three molecular subtypes of
MIBC that resembled established molecular subtypes of breast cancer. Basal MIBCs shared biomarkers
with basal breast cancers and were characterized by p63 activation, squamous differentiation, and more
aggressive disease at presentation. Luminal MIBCs contained features of active PPARg and estrogen recep-
tor transcription and were enriched with activating FGFR3mutations and potential FGFR inhibitor sensitivity.
p53-like MIBCs were consistently resistant to neoadjuvant methotrexate, vinblastine, doxorubicin and
cisplatin chemotherapy, and all chemoresistant tumors adopted a p53-like phenotype after therapy. Our ob-
servations have important implications for prognostication, the future clinical development of targeted
agents, and disease management with conventional chemotherapy.INTRODUCTION
Bladder cancer progresses along two distinct pathways that
pose distinct challenges for clinical management (Dinney et al.,
2004). Low-grade non-muscle invasive (‘‘superficial’’) cancers,
which account for 70% of tumor incidence, are not immediately
life-threatening, but they have a propensity for recurrence that
necessitates costly lifelong surveillance (Botteman et al., 2003).
In contrast, high-grade muscle-invasive bladder cancers
(MIBCs) progress rapidly to become metastatic and generateSignificance
Using whole genomemRNA expression profiling, we identified
(MIBC) that shared molecular features with basal and luminal
p53 gene signature, and these ‘‘p53-like’’ MIBCs were consiste
bination chemotherapy. Furthermore, comparison of matche
revealed that all resistant tumors expressed wild-type p53 ge
‘‘p53-ness’’ plays a central role in chemoresistance in bladder c
identify the patients who most likely will not benefit from neoa
152 Cancer Cell 25, 152–165, February 10, 2014 ª2014 Elsevier Inc.the bulk of patient mortality (Shah et al., 2011). Radical cystec-
tomy with perioperative cisplatin-based combination chemo-
therapy is the current standard of care for high-risk MIBC.
Treatment selection depends heavily on clinico-pathologic
features, but current staging systems are woefully inaccurate
and result in an unacceptably high rate of clinical understaging
and consequently inadequate treatment (Svatek et al., 2011).
Furthermore, cisplatin-based chemotherapy is only effective in
30%–40% of cases, and it is not yet possible to prospectively
identify the patients who are likely to obtain benefit (Shahthreemolecular subtypes of muscle-invasive bladder cancer
breast cancers. Tumors in one of them expressed an active
ntly resistant to frontline neoadjuvant cisplatin-based com-
d gene expression profiles before and after chemotherapy
ne expression signatures. Together, the data indicate that
ancer and suggest that it should be possible to prospectively
djuvant chemotherapy.
Figure 1. Basal and Luminal Subtypes of Bladder Cancer
(A) Left:whole genomemRNAexpressionprofilingandhierarchical cluster analysis of a cohort of 73MIBCs.RNA from fresh frozen tumorswasanalyzedusing Illumina
arrays.RAS, TP53,RB1, and FGFR3mutationswere detected by sequencing and are indicated in the color bars below the dendrogram.Black,mutation; white, wild-
type;gray,mutationdatawereunavailable.Right:Kaplan-Meierplotsofoverall survival (p=0.098)anddisease-specificsurvival (p=0.028) in the three tumor subtypes.
(B) Expression of basal and luminal markers in the three subtypes. The heat maps depict relative expression of basal (left) and luminal (right) biomarkers. GSEA
analyses (below, left) were used to determine whether basal and luminal markers were enriched in the subtypes.
(C) Quantitative RT-PCRwas used to evaluate the accuracy of the gene expression profiling results. Relative levels of the indicated basal (red shades) and luminal
(blue shades) biomarkers measured by RT-PCR were compared to the levels of the same markers measured by gene expression profiling on RNA isolated from
macrodissected FFPE sections of the same tumors. Results are presented as relative quantitation (RQ) and the error bars indicate the range of RQ values as
defined by 95% confidence level. RT-PCR results are shown on top, DASL gene expression profiling results are shown below.
(D) Analysis of basal and luminal marker expression by immunohistochemistry. Results from two representative basal (left) and luminal (right) tumors as defined by
gene expression profiling are displayed. The scale bars correspond to 100 mm.
See also Figure S1.
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Table 1. Clinicopathologic Characteristics of the MDACC Discovery Cohort
Characteristic Total Basal p53-like Luminal p Value
Cohort size 73 23 (32%) 26 (36%) 24 (33%)
Mean age (years) ± SD 68.8 ± 10.2 70.1 ± 9.4 69.8 ± 8.9 66.4 ± 12.1 0.371
Gender
Female 19 (26%) 10 (44%) 6 (23%) 3 (13%) 0.133
Male 54 (74%) 13 (57%) 20 (77%) 21 (88%)
Race
Caucasian 54 (74%) 14 (61%) 21 (81%) 19 (79%) 0.352
African American 12 (16%) 6 (26%) 2 (7%) 4 (17%)
Hispanic 7 (10%) 3 (13%) 3 (12%) 1 (4%)
Clinical stage at TUR (N0,M0)
%cT1 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0.990
cT2 37 (51%) 9 (39%) 16 (62%) 12 (50%)
cT3 16 (22%) 4 (17%) 7 (27%) 5 (21%)
cT4 6 (8%) 2 (9%) 2 (8%) 2 (8%)
Positive clinical lymph nodes, cN+ 11 (15%) 5 (22%) 1 (4%) 5 (21%) 0.137
Positive clinical metastasis, cM+ 7 (10%) 5 (22%) 0 (0%) 2 (8%) 0.035
Primary treatment
Cystectomy 57 (78%) 15 (65%) 25 (96%) 17 (71%) 0.019
Othera 16 (22%) 8 (35%) 1 (4%) 7 (29%)
Neoadjuvant Chemotherapy, NAC 18 (25%) 5 (22%) 7 (27%) 6 (25%) 0.910
Response to NACb
Yes 6 (33%) 2 (40%) 0 (0%) 4 (67%) 0.018
No 12 (67%) 3 (60%) 7 (100%) 2 (33%)
Pathologic T stage (n = 57)
pT0 4 (7%) 2 (13%) 0 (0%) 2 (12%) 0.001
pTa, pT1, pTis 6 (11%) 2 (13%) 1 (4%) 3 (18%)
pT2 10 (18%) 1 (7%) 4 (16%) 5 (29%)
pT3 25 (44%) 4 (27%) 18 (72%) 3 (18%)
pT4 12 (21%) 6 (40%) 2 (8%) 4 (22%)
Positive pathologic lymph nodes 23 (40%) 3 (13%) 14 (54%) 6 (25%) 0.010
Variant histology in specimen
Squamous differentiation 18 (32%) 13 (57%) 4 (15%) 1 (4%) <0.001
Sarcomatoid differentiation 3 (5%) 3 (13%) 0 (0%) 0 (0%)
Other (micropapillary, glandular, adenocarcinoma) 3 (5%) 0 (0%) 3 (12%) 0 (0%)
Median overall survival (months) 37.2 14.9 34.6 65.6 0.098
Median disease-specific survival (months) 46.3 14.9 not reached 65.6 0.028
The Kruskal-Wallis test was used to compare differences in mean age between groups. Log-rank test was used to compare differences in survival
(overall and disease-specific) between groups. For the remainder of categorical variables, Fisher’s exact test was used to determine differences
between subtypes. p values < 0.05 were considered significant.
aChemotherapy was recommended for all 16 patients, based on available medical records; nine patients had documentation of completion.
bDecrease in stage to pT0 or pT1 (for patients with high-risk features at TUR: lymphovascular invasion, variant histology, hydronephrosis, or abnormal
exam under anesthesia) at cystectomy.
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cisplatin-based chemotherapy has been identified for resistant
tumors. Therefore, there is an urgent need to develop a more
precise, biology-based approach to the classification of bladder
cancer to inform clinical management.
Gene expression profiling has been used to identify molecular
heterogeneity in other human cancers. For example, Perou and
coworkers (Perou et al., 2000) used gene expression profiling
to identify molecular subtypes of breast cancer (basal/triple154 Cancer Cell 25, 152–165, February 10, 2014 ª2014 Elsevier Inc.negative, HER2+, luminal A, and luminal B) that behave clinically
as though they are distinct disease entities—luminal breast can-
cers respond to estrogen receptor (ER)-targeted therapy, HER2+
tumors to Herceptin and other ErbB2-blocking agents, and basal
tumors to chemotherapy only (Rouzier et al., 2005). Previous
studies in bladder cancer identified signatures associated with
stage and outcomes (Blaveri et al., 2005; Dyrskjøt et al., 2003;
Sanchez-Carbayo et al., 2006; Sjodahl et al., 2012) and progres-
sion (Kim et al., 2010; Lee et al., 2010), but the biological and
(legend on next page)
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also used gene expression profiling and unsupervised analyses
to identify molecular subtypes of MIBC with the goal of defining
the biological basis for the molecular heterogeneity that is
observed in them.
RESULTS
Muscle-Invasive Bladder Cancers Can Be Grouped into
Basal and Luminal Subtypes
We performed whole genome mRNA expression profiling and
unsupervised hierarchical cluster analyses on a cohort of 73
primary fresh-frozen MIBCs obtained by transurethral resection
at our institution. We identified three distinct molecular subtypes
(Figure 1A; Table 1). The upregulated genes (fold changes) that
determined subtype assignments contained signature bio-
markers for basal (CD44, KRT5, KRT6, KRT14, and CDH3) and
luminal (CD24, FOXA1, GATA3, ERBB2, ERBB3, XBP1, and
KRT20) breast cancers, respectively (Figure 1B, heat maps; Fig-
ure S1A available online; Perou et al., 2000), and formal gene set
enrichment analyses (GSEA) confirmed that the subtypes were
enriched with basal and luminal markers (Figure 1B, below). In
control experiments, we confirmed that the array-based mea-
surements of basal and luminal marker expression correlated
well with the results obtained with quantitative RT-PCR (Fig-
ure 1C) or immunohistochemistry (Figure 1D) in some of the
same tumors. We therefore propose the names ‘‘basal’’ and
‘‘luminal’’ for two of the MIBC subtypes. Although the tumors
in the third subtype also expressed luminal biomarkers
(Figure 1B; Figure S1A), we have termed this MIBC subtype
‘‘p53-like’’ because its distinguishing feature was an activated
wild-type p53 gene expression signature that we will discuss
further below.
Table 1 depicts the clinical and pathologic characteristics of
the discovery cohort by molecular subtype. Basal tumors were
enriched with sarcomatoid features and metastatic disease at
presentation (Table 1) and were associated with shorter overall
survival (14.9 months, p = 0.098), and disease-specific survival
(median 14.9 months, p = 0.028; Figure 1A, right). Although
they expressed epithelial cytokeratins, basal tumors also con-
tained ‘‘mesenchymal’’ biomarkers (i.e., TWIST1/2, SNAI2,
ZEB2, and VIM;McConkey et al., 2010; Peinado et al., 2007; Fig-
ure S1B), as do basal breast cancers (Chaffer et al., 2013). In
addition, basal tumors expressed high levels of the epidermal
growth factor receptor (EGFR) and several of its ligands (Fig-
ure S1B), similar to basal breast and head and neck squamousFigure 2. Characterization of Basal and Luminal Subtypes in other MIB
(A) Subtype classification of the MD Anderson validation cohort (n = 57). RNA was
expression was measured using Illumina’s DASL platform. Kaplan-Meier plots of
with the three subtypes are presented on the right.
(B) Expression of basal and luminal markers in the molecular subtypes in the
marker expression in the subtypes are displayed on the left, and heat maps depi
the right.
(C) Subtype classification of the Chungbuk cohort (n = 55). Whole genomemRNA
GEO (GSE13507), and the oneNN classifier was used to assign tumors to subtype
Kaplan-Meier plots of overall survival (p = 0.102) and disease-specific survival (p
(D) Expression of basal and luminal markers in the molecular subtypes in the Chun
subtypes are displayed on the left, and heat maps depicting basal and luminal m
See also Tables S1 and S2.
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et al., 2001). On the other hand, luminal tumors were enriched
with ‘‘epithelial’’ biomarkers (E-cadherin/CDH1 and members
of the miR-200 family; Gregory et al., 2008; Figure S1B), high
levels of fibroblast growth factor receptor-3 (FGFR3), and acti-
vating FGFR3 mutations (Figures 1A and 1B; Figure S1C).
TP53 mutation frequencies were similar in all of the subtypes
(Figure S1C). To examine cluster stability, we calculated silhou-
ette scores for each subtype. All of the basal and luminal tumors
were stable, whereas 9/26 of the p53-like tumors were not (Fig-
ure S1D); five of these unstable tumors were most similar to the
luminal subtype (data not shown).
We developed a classifier using the differentially expressed
genes associated with subtype membership in the discovery
cohort and applied it to whole genome mRNA expression
data from an independent cohort of formalin-fixed paraffin-
embedded MIBCs (n = 57, MD Anderson validation cohort; Fig-
ure 2A; Table S1). Like the discovery cohort, basal tumors in the
validation cohort were associated with shorter overall survival
(median 25.0 months, p = 0.011) and disease-specific survival
(median 25.3 months, p = 0.004; Figure 2A, right side) and
were enriched with basal biomarkers compared to tumors in
the other subtypes (Figure 2B). We then used the classifier to
make additional predictions in the MIBCs (n = 55) from a third,
publicly available gene expression profiling data set (‘‘Chungbuk
cohort’’; Kim et al., 2010; Figure 2C; Table S2). The Chungbuk
basal tumors were also associated with shorter median dis-
ease-specific survival (11.2 months, p = 0.102) and overall
survival (10.4 months, p = 0.058; Figure 2C, right side) and
were enriched with basal biomarkers (Figure 2D). In addition,
GSEA confirmed that luminal biomarkers were enriched in
luminal subtypes in both of the validation cohorts (Figures 2B
and 2D).
Basal Tumors Are Characterized by Squamous
Differentiation
Bladder cancers with squamous histological features are gener-
ally considered distinct from conventional urothelial cancers.
However, the basal MIBCs in the discovery and validation co-
horts were significantly enriched with squamous features (Fig-
ure 3A; Table 1; Table S1), and the basal tumors with squamous
features also expressed higher basal biomarker mRNA levels
than did basal tumors without squamous features (data not
shown). The high molecular weight keratins (KRT5, KRT6, and
KRT14) that characterized basal MIBCs were also enriched in
a lethal ‘‘squamous cell carcinoma’’ MIBC subtype that wasC Cohorts
isolated frommacrodissected FFPE tumor sections and whole genomemRNA
overall survival (p = 0.011) and disease-specific survival (p = 0.004) associated
MD Anderson validation cohort. The results of GSEA of basal and luminal
cting relative basal and luminal marker levels in the subtypes are displayed on
expression profiling (Illumina platform) and clinical data were downloaded from
s. Tumors were assigned to subtypes using the oneNN prediction model (left).
= 0.058) as a function of tumor subtype (right).
gbuk cohort. The results of GSEA of basal and luminal marker expression in the
arker expression are displayed on the right.
Figure 3. Presence of Squamous Features in the Subtypes
(A) Tumor squamous feature content in the MD Anderson discovery and validation cohorts. Subtype designations are indicated by the top color bars, and the
presence of squamous features (in black) is indicated in the color bars below.
(B) Relationship between the MD Anderson subtypes and the molecular taxonomy developed by Sjodahl and colleagues (Sjodahl et al., 2012). Whole genome
mRNA expression (Illumina platform) and clinical data were downloaded from GEO (GSE32894), and the oneNN classifier was used to assign the Lund tumors to
subtypes. Subtype membership is indicated by the top color bars, and FGFR3 and TP53mutations in the Lund tumors are indicated in color bars below. Black,
mutant; white, wild-type; gray (N/A), mutation data were not available.
(C) Presence of squamous features in the UCSF data set. Gene expression profiling (in-house platform) and clinical data were downloaded fromGEO (GSE1827),
and the oneNN classifier was used to assign the UCSF tumors to the subtypes. Subtype memberships for each tumor are indicated in the top color bars, and the
presence of squamous features (in black) is indicated in the color bar below.
(legend continued on next page)
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applied our subtype classifier to the other group’s data set
(‘‘Lund cohort’’; Sjodahl et al., 2012) and confirmed that the
Lund squamous cell carcinoma subtype (Sjodahl et al., 2012)
corresponded to the basal subtype identified here (‘‘Lund’’
tumors, Figure 3B; Table S3). Furthermore, like theMDAnderson
discovery and validation cohorts, the Lund basal/SCC-like
tumors were enriched with squamous differentiation (Sjodahl
et al., 2012). Other Lund features also correlated with the sub-
types described here—the MD Anderson p53-like subtype and
the Lund ‘‘infiltrated’’ (MS2b.1) tumors were enriched with extra-
cellular matrix biomarkers (Figure 3B; also see Figure S2; Sjodahl
et al., 2012), and all of the Lund ‘‘urobasal A’’ tumors were
confined to the MD Anderson luminal subtype (Figure 3B). In
addition, as was the case in the MD Anderson discovery cohort,
the Lund luminal tumors were enriched with activating FGFR3
mutations (p < 0.05; Figure 3B; Figure S1C). High molecular
weight keratins (KRT5 and KRT14) also characterized a bladder
cancer ‘‘squamous cluster’’ (cluster D) identified by a group at
the University of California-San Francisco (‘‘UCSF cohort’’; Bla-
veri et al., 2005). We applied our classifier to the UCSF data set
and confirmed that the UCSF basal tumors were also enriched
with squamous features (Figure 3C; ‘‘UCSF,’’ Table S4). Finally,
we stained a tissue microarray containing 332 pT3 MIBCs (Table
S5) with clinical-grade antibodies specific for basal (CK5/6) or
luminal (CK20) cytokeratins, quantified antigen expression
across the tissue microarray by image analysis, and correlated
cytokeratin levels with the presence of squamous features (Fig-
ure 3D). Mean CK5/6 levels were significantly higher in tumors
with squamous differentiation, whereas CK20 was expressed
at higher levels in conventional MIBCs, and expression of CK5/
6 correlated inversely with CK20 across the cohort (Figure 3D).
Expression of CK5/6 did not correlate with adverse outcomes
(data not shown) because careful stage matching had been per-
formed in the tumor cohort. Together, the results demonstrate
that squamous differentiation is a common feature of basal
MIBCs and that the subtypes described here are similar to those
identified independently by other groups.
p63 and PPARg Control Basal and Luminal Biomarker
Expression
To more clearly define the transcription factors that controlled
basal and luminal gene expression, we used the ‘‘upstream
regulators’’ function in Ingenuity Pathway Analysis (IPA, Ingenu-
ity Systems; http://www.ingenuity.com) and the gene expres-
sion profiling data from the MD Anderson discovery cohort to
identify the transcription factors that were responsible for the
gene expression signatures observed in theMIBC subtypes (Fig-
ure 4; Table S6). Because the silhouette analyses revealed that
nine of the p53-like tumors were unstable, we compared the
IPA results obtained with (n = 73) and without (n = 64) the unsta-(D) Tissue microarray analysis of CK5/6 (basal) and CK20 (luminal) cytokeratin
chemistry and optical image analysis in the MD Anderson Pathology Core on a
positive tumor cells as determined by image analysis are shown. Left panels: mea
with SD) squamous features. Bars indicate mean values with 95% confidence inte
expressed high or low levels of CK5/6 or CK20. The scale bars correspond to 100
cohort.
See also Tables S3–S5 and Figure S2.
158 Cancer Cell 25, 152–165, February 10, 2014 ª2014 Elsevier Inc.ble tumors (Table S7). Transcription factors that have been impli-
cated in the biology of the basal/stem cell compartment of the
normal urothelium (Stat-3, NFkB, Hif-1, and p63; Ho et al.,
2012) were predicted to be significantly ‘‘activated’’ in basal
MIBCs (Figure 4; Table S6; Figure S3A). TP63 has been identified
as a biomarker for lethal MIBCs (Choi et al., 2012; Karni-Schmidt
et al., 2011), and we used quantitative RT-PCR to confirm that
TP63 levels were elevated in the basal MIBCs in the MD Ander-
son discovery cohort (Figure S3B). Six of the top ten upregulated
basal MIBC biomarkers (KRT5, KRT6A, KRT6C, PI3, KRT14, and
S100A7) based on fold changes are known direct DNp63a
transcriptional targets in other tissues (Boldrup et al., 2007; Celis
et al., 1996; Romano et al., 2009; Figure 4, also Figure 1B). Basal
tumors were also enriched for MYC expression, which is
controlled by p63 in human bladder cancer cells (Marquis
et al., 2012).
Luminal MIBCs exhibited strong peroxisome proliferator
activator receptor (PPAR) pathway activation as well as high-
level expression of PPARG and its direct transcriptional target
and coactivator, FABP4 (Figures 1B and 4; Table S6; Ayers
et al., 2007). In addition, the estrogen receptor (ER) and its
coactivator Trim-24 (Hatakeyama, 2011; Tsai et al., 2010) were
among the top ‘‘activated’’ upstream regulators in the luminal
MIBCs, whereas the basal Stat-3 and NFkB transcriptional
networks were downregulated in them (Table S6; Figures S3C
and S3D). Conversely, breast luminal transcriptional pathways
(ER, Gata-3, and Trim-24) were all downregulated in the
basal MIBCs (Table S6). The p53-like luminal MIBCs could
be distinguished from the luminal tumors by their expression
of an active p53-associated gene expression signature that
was not associated with the presence of wild-type TP53 (Fig-
ure 4; also Figures 1 and 3B; Tables S6 and S7). The p53-like
tumors also contained an active p16 (CDKN2A) gene signature
(Figure S3E).
To more directly define p63’s role in controlling basal gene
expression, we stably transduced human UM-UC14 bladder
cancer cells with nontargeting or TP63-specific shRNAs and
used whole genome mRNA expression profiling to create a
bladder cancer p63 pathway gene expression signature. IPA
analyses indicated that TP63 knockdown decreased basal
(p63 and Myc) pathway gene expression, and interestingly, it
also increased PPAR pathway gene expression (Figure 5A; Fig-
ure S4A). GSEA analyses in the discovery cohort confirmed
that the p63 gene signature was significantly enriched in primary
basal MIBCs (Figure 5B).
To determine PPARg’s role in controlling luminal gene expres-
sion, we generated PPARg gene expression signatures using
whole genome mRNA expression profiling data collected from
two human bladder cancer cell lines (UM-UC7 and UM-UC9)
that had been exposed to the PPARg-selective agonist rosiglita-
zone. IPA analyses confirmed that rosiglitazone activated PPARexpression. Cytokeratin protein expression was measured by immunohisto-
tissue microarray containing 332 high-grade pT3 tumors. The percentages of
n levels of CK5/6 (top) and CK20 (bottom) in tumors without (TCC) or with (TCC
rvals. Middle panels: representative images of stained cores from tumors that
mm. Right panel: relationship between CK5/6 and CK20 expression across the
Figure 4. Subtype-Associated Gene
Expression Signatures
Signatures were identified using the whole
genome mRNA expression profiling data from the
MD Anderson discovery cohort and the upstream
regulators tool in Ingenuity Pathway Analysis (IPA,
Ingenuity Systems; http://www.ingenuity.com).
Each heat map displays the expression of the
corresponding IPA gene signature as a function
of tumor subtype membership; note that genes
can be either up- or downregulated by an active
transcription factor. Top left: p63-associated
gene expression. Bottom left: PPARg-associated
gene expression. Right: p53-associated gene
expression.
See also Tables S6 and S7 and Figure S3.
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(Figure 5A; Figures S4B and S4C). GSEA revealed that the
UM-UC7 and UM-UC9 PPARg gene signatures were signifi-
cantly enriched in primary luminal MIBCs in the discovery cohort
(Figure 5B). Interestingly, rosiglitazone also decreased basal
transcription factor activation (Figure 5A; Figure S4C). Therefore,
PPARg activation plays an important role in regulating theCancer Cell 25, 152–165,luminal MIBC gene expression signature,
and p63 and PPARg antagonize each
other.
p53-like MIBCs Are Resistant to
Neoadjuvant Chemotherapy
Presurgical (neoadjuvant) cisplatin-
based chemotherapy (NAC) is the current
standard-of-care for high-risk MIBC
(Shah et al., 2011), and pathological
response to NAC (downstaging to%pT1
at cystectomy) is a strong predictor of
disease-specific survival (Grossman
et al., 2003), as it is in breast cancer
(Esserman et al., 2012b). We noticed
that all of the p53-like MIBCs from
patients treated with NAC in the discov-
ery cohort (n = 7) were resistant to
chemotherapy (Table 1). To examine this
relationship further, we explored the
chemoresistance of p53-like MIBCs in
an expanded NAC cohort (n = 34) and in
an additional cohort of 23 archival tumors
treated uniformly with methotrexate,
vinblastine, doxorubicin and cisplatin
(MVAC) within the context of a Phase III
clinical trial (Millikan et al., 2001). The
p53-like MIBCs in both cohorts were
resistant to NAC (Figure 6A; Tables S8
and S9). We applied the primary tumor
p53 signature to a panel of human
bladder cancer cell lines and identified a
subset of them that expressed the signa-
ture, not all of which retained wild-type
TP53 (Figure 6B). The p53-like cell lineswere also resistant to cisplatin-induced apoptosis in vitro (Fig-
ure 6C). In addition, four of five of the TP53 wild-type cell lines
that did not contain the ‘‘p53-like’’ signature at baseline were
cisplatin-resistant (Figures 6B and 6C).
To further examine whether chemoresistance was a consis-
tent feature of the p53-like subtype, we used gene expression
profiling and our classifier to perform molecular subtypeFebruary 10, 2014 ª2014 Elsevier Inc. 159
(legend on next page)
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collected within the context of a prospective Phase II clinical trial
of neoadjuvant dose-denseMVAC (DDMVAC), conducted at Fox
Chase Cancer Center and Thomas Jefferson University Hospital
(Table S10). All of the pretreatment tumors with squamous
features in this ‘‘Philadelphia’’ cohort were confined to the basal
cluster (Table S10; p = 0.012). In addition, and consistent with
what we had observed in the MD Anderson cohorts, many of
the Philadelphia basal (7/14) and luminal (12/20) tumors re-
sponded to NAC, whereas the response rate in the p53-like
tumors was significantly lower at 11% (1/9; Figure 7A). Further-
more, chemoresistant tumors were enriched with the p53-like
subtype after NAC (Figure 7B).
To further characterize the molecular mechanisms underlying
chemoresistance, we compared the matched pre- and post-
treatment gene expression profiles of the chemoresistant Phila-
delphia tumors using the ‘‘upstream regulators’’ function of IPA
(data not shown). The results indicated that chemotherapy
caused all of the tumors to express an active p53 pathway
gene signature after NAC (Figure 7C; Table S11). Importantly,
this chemotherapy-induced p53 signature was not very similar
to the one that dictated tumor membership within the p53-like
subtype (13 overlapping probes, Table S11).
Finally, we searched for pretreatment gene signatures within
the Philadelphia basal and luminal MIBC subtypes that might
predict chemosensitivity. We were unable to detect such a
signature in the luminal tumors (data not shown), but the chemo-
sensitive Philadelphia basal tumors were enriched for bio-
markers reflective of immune infiltration (Figure 7D). Similarly,
all of the chemosensitive basal tumors from the MD Anderson
MVAC cohort were also enriched with these immune biomarkers
(Figure S5).
DISCUSSION
We conclude that MIBCs can be grouped into basal and luminal
subtypes reminiscent of those observed in human breast can-
cers (Perou et al., 2000). Basal MIBCs were associated with
shorter disease-specific and overall survival, presumably
because patients with these cancers tended to have more
invasive and metastatic disease at presentation. The invasive/
metastatic phenotype was associated with expression of
‘‘mesenchymal’’ and bladder cancer stem cell (Chan et al.,
2009) biomarkers, and the tumors were enriched with sarcoma-
toid and squamous features (Blaveri et al., 2005; Sjodahl et al.,
2012). The link between squamous features and aggressive
behavior is consistent with other recent observations (Kim
et al., 2012; Mitra et al., 2013), and the presence of EMT andFigure 5. Transcriptional Control of the Basal and Luminal Gene Expre
Whole genomemRNA expression profiling was used to analyze the effects of stab
cancer cell lines, and the data were used to generate gene expression signatures
whether these signatures were present in the MD Anderson discovery cohort tum
(A) Effects of p63 or PPARgmodulation on basal and luminal transcriptional signat
p63 knockdown in UM-UC14 cells (top left), PPARg activation in UM-UC7 (top m
heat maps below each graph indicate significant changes in basal and luminal m
(B) p63 and PPARg gene expression signatures in the subtypes of primary MIBC
up- and downregulated genes in each condition. ROSI, rosiglitazone.
See also Figure S4.
Cbladder cancer stem cell biomarkers in basal tumors provides
a biological explanation for their aggressive behaviors. Tran-
scription factor p63 plays a central role in controlling the basal
gene signature, and our preliminary data suggest that the
EGFR, Stat-3, NFkB, and Hif-1a are also involved. Importantly,
immune-infiltrated basal MIBCs responded to NAC, as do
some basal breast cancers (Esserman et al., 2012a, 2012b).
Because NAC pathological complete response is associated
with excellent long-term survival (Grossman et al., 2003),
aggressive early management of basal MIBCs with NAC offers
the best chance for improved survival for patients with this
potentially deadly form of this disease. It also seems likely that
T cell modulators (i.e., anti-CTLA4) and EGFR-, NFkB, Hif-1a/
VEGF, and/or Stat-3-targeted agents will also be active within
this subtype.
Like luminal breast cancers (Perou et al., 2000; Sørlie et al.,
2001), luminal MIBCs displayed active ER/TRIM24 pathway
gene expression and were enriched with FOXA1, GATA3,
ERBB2, and ERBB3. Agents that target the ER (George et al.,
2013; Hoffman et al., 2013; Shen et al., 2006) and/or ErbB2
and -3 may therefore be clinically active in luminal MIBCs. In
addition, luminal MIBCs contained active PPAR gene expression
and activating FGFR3 mutations, so PPARg- and FGFR-3-
targeted agents may be active in this subtype. Because many
luminal MIBCs responded to NAC, targeted therapies should
probably be combined with conventional chemotherapy for
maximum efficacy.
The idea that wild-type p53 is required for DNA damage-
induced apoptosis is a central tenet in cancer biology (Lowe
et al., 1993, 1994). Therefore, it was surprising to us that de
novo and induced chemoresistance in MIBCs was associated
with wild-type p53 gene expression signatures. Nevertheless,
this link between ‘‘p53-ness’’ and chemoresistance is another
shared property of MIBCs and luminal breast cancers. The
recently completed I-SPY 1 TRIAL (‘‘Investigation of Serial
Studies to Predict Your Therapeutic Response With Imaging
and Molecular Analysis,’’ CALGB150007/150012) examined
the correlation between pathological complete response (pCR)
rates and recurrence-free and overall survival in women treated
with NAC. One of its main conclusions was that pCR rates varied
markedly within the different breast cancer subtypes such that
tumors with luminal A and/or wild-type p53-like gene expression
signatures responded very poorly to NAC (Esserman et al.,
2012a, 2012b). Wild-type p53-induced reversible senescence
has also recently been implicated in chemoresistance in amouse
model of breast cancer (Jackson et al., 2012), and more gener-
ally, quiescence is considered an important mechanism of
chemoresistance. Importantly, TP53 mutation frequenciesssion
le p63 knockdown or rosiglitazone-induced PPARg activation in human bladder
characteristic of p63 and PPARg activation. GSEA was then used to determine
or subtypes.
ures. Top panels: significantly activated/inhibited transcriptional pathways after
iddle), or PPARg activation in UM-UC9 (top right) based on IPA analyses. The
arker expression.
s. Separate results and p values are shown for the signatures derived from the
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Figure 6. Relationship between Subtype Membership and Chemotherapy Sensitivity
(A)Responses toneoadjuvantchemotherapy in theMDAndersonNAC (n=34) andMVAC(n=23)cohorts.Subtypemembershipwasdeterminedusingwholegenome
mRNA expression profiling data obtained from untreated (TURBT) tumors and the oneNN classifier. Pathological response was defined as downstaging to%pT1.
(B) The IPA-defined p53 gene expression signature from the p53-like primary MIBCs was used to perform unsupervised hierarchical cluster analysis on whole
genome expression data from a panel of human bladder cancer cell lines (n = 28). The green boxes on the heat maps indicate expression of the signature in the
MDAnderson discovery cohort (left) or the cell lines (right). TP53mutational status was determined by sequencing and is indicated by the color bar below the heat
map (black, mutant; white, wild-type; gray, data were not available).
(C) Cells were incubated with or without 10 mM cisplatin for 48 hr and apoptosis-associated DNA fragmentation was quantified by propidium iodide staining and
FACS analysis in three independent experiments. The left panel displays a scatter gram comparing the levels within the two subsets of cell lines (mean ± SEM).
The right panel displays the mean value of induced apoptosis in each cell line across the entire cohort.
See also Tables S8 and S9.
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p53-ness and Chemoresistance in Bladder Cancerwere similar in all three MIBC subtypes, indicating that wild-type
p53 was not responsible for the baseline and chemotherapy-
induced p53-like gene expression signatures reported here.162 Cancer Cell 25, 152–165, February 10, 2014 ª2014 Elsevier Inc.We therefore propose that ‘‘p53-ness’’ as measured by mRNA
expression would be a more accurate predictor of de novo and
induced MIBC chemoresistance than would analyses of TP53
Figure 7. Wild-Type p53 Gene Signatures in
Tumors before and after Treatment with
NAC
(A) Relationship between subtype membership
and response to NAC in the Philadelphia DDMVAC
cohort. Subtype membership was determined
using pretreatment (TURBT) specimens. Patho-
logical response was defined as downstaging to
% pT1.
(B) Comparison of subtype membership in the
chemoresistant Philadelphia tumors before and
after NAC. Whole genome mRNA expression
profiling was performed on matched tumors
before and after NAC, and the oneNN classifier
was used to assign tumors to subtypes. ‘‘TURBT’’
refers to the pretreatment tumors and ‘‘cys-
tectomy’’ to the post-treatment tumors.
(C) Expression of a wild-type p53 gene signature
in matched pre- and post-treatment tumors. Left:
heat map displaying expression of an active p53
gene signature after NAC (log ratio cystectomy/
TURBT of matched tumors). Right: relative
expression of the p53 signature in matched pre-
and post-treatment tumors arranged according to
subtype membership.
(D) Analysis of an immune infiltration signature
in basal tumors. A supervised analysis was per-
formed to compare the differences in gene ex-
pression between basal tumors that were either
sensitive or resistant to neoadjuvant DDMVAC in
the Philadelphia cohort. Left: heat map depicting
the relative expression of immune signature genes
in basal responders and non-responders. Right:
GSEA analyses of immune biomarkers in the basal
tumors.
See also Tables S10 and S11 and Figure S5.
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p53-ness and Chemoresistance in Bladder Cancermutational status. It will be important to determine the molecular
basis of these p53-like signatures in future studies so that thera-
peutic approaches can be developed to overcome de novo and/
or prevent acquired chemoresistance. We also plan to prospec-
tively test the relationship between the p53-like phenotype and
chemoresistance within the context of a SWOG-sponsored
multicenter clinical trial (S1314) that is very similar to I-SPY and
was designed to prospectively evaluate another gene expres-
sion profiling-based algorithm (‘‘CoXEN’’; Lee et al., 2007).
EXPERIMENTAL PROCEDURES
Technical details are provided in the Supplemental Experimental Procedures.
Human Specimens
Clinical data were obtained from the MD Anderson Genitourinary Cancers
Research Database, from the Gene Expression Omnibus (GEO), or from
patient charts (MVAC and Philadelphia cohorts). All MD Anderson patients
signed a ‘‘front door’’ informed consent allowing collection of their tissueCancer Cell 25, 152–165,and of their clinical data that was approved by
the MD Anderson Institutional Review Board
(IRB). An additional MD Anderson IRB-approved
protocol was obtained specifically for genomics
analyses. The Philadelphia tissues were collected
and analyzed as part of a Phase II clinical trial that
was IRB-approved at the Fox-Chase Cancer
Center and Thomas Jefferson University. Un-stained tissue sections (10 micron, five slides/tumor) and matched hematoxy-
lin and eosin stained sections from the DDMVAC clinical trial were transferred
toMD Anderson under an executedmaterials transfer agreement betweenMD
Anderson and Fox-Chase. A genitourinary pathologist (Bogdan Czerniak) re-
viewed all of the tissue samples.
Tumor Cohorts
The Chungbuk (n = 55) (Kim et al., 2010), Lund (n = 93) (Sjodahl et al., 2012),
and UCSF (n = 53)(Blaveri et al., 2005) cohort data were downloaded from
the GEO (GSE13507, GSE32894, and GSE1827, respectively). The discovery
cohort consisted of 73 tumors from transurethral resections (TURs) that had
been snap-frozen in liquid nitrogen within 5 min of isolation and transferred
to theMDAnderson Bladder SPORE Tissue Core. TheMDAnderson validation
cohort consisted of 57 randomly selected, formalin-fixed, paraffin-embedded
(FFPE) tumors that were obtained from the main MD Anderson Cancer Center
CCSG-supported Pathology Tissue Bank. The MD Anderson NAC cohort (n =
34) contained a mixture of 18 tumors from the discovery cohort plus 16
additional FFPE tumors from patients treated with neoadjuvant chemotherapy
on- and off-protocol. The MD Anderson MVAC cohort (n = 23) consisted of all
available FFPE pretreatment tumors (TURs) from a previously reported PhaseFebruary 10, 2014 ª2014 Elsevier Inc. 163
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p53-ness and Chemoresistance in Bladder CancerIII clinical trial (Millikan et al., 2001). The Philadelphia NAC cohort (n = 43 TURs
and 20 cystectomies) consisted of all available pre- and post-treatment FFPE
tumors from patients enrolled in a Phase II clinical trial of neodjuvant dose-
dense MVAC (DDMVAC) that was conducted at Fox-Chase Cancer Center
and The Thomas Jefferson University and will be reported elsewhere. NAC
response in all of the cohorts was defined as downstaging to no muscle-inva-
sive disease at cystectomy (%pT1; Millikan et al., 2001).Gene Expression Profiling Platforms
The MD Anderson discovery cohort and human bladder cancer cell lines were
analyzed by direct hybridization on Illumina HT12v3 and HT12v4 chips,
respectively (Illumina). Data from all of the FFPE cohorts were generated using
Illumina’s DASL platform (WG-DASL HT12v4 chips).
Tumor Cluster Assignments
MIBC clusters (subtypes) were determined in the discovery cohort using un-
supervised hierarchical cluster analysis (Eisen et al., 1998). The gene signa-
tures associated with each cluster were then used to generate a one nearest
neighbor (oneNN; Dudoit et al., 2002) prediction model that was used in all
subsequent analyses to assign tumors to specific subtypes.Micro RNA Expression
Levels of miR-200b and miR-200c were measured in the discovery cohort
by quantitative RT-PCR as described in the Supplemental Experimental
Procedures.
Analysis of Cytokeratin Protein Expression
Basal (CK5/6) and luminal (CK20) cytokeratin protein expression was analyzed
on a tissue microarray (TMA) consisting of stage-matched (pT3, n = 332)
MIBCs collected within the context of the International Bladder Cancer
Network’s Bladder Cancer Bank initiative (Goebell et al., 2005). Immunohisto-
chemical staining was performed using clinical-grade (CLIA) antibodies and
protocols in the MD Anderson Pathology Core, and staining intensities were
quantified by image analysis.
Generation of p63 and PPARg Gene Signatures
UM-UC14 human MIBC cells were stably transduced with TP63-specific or
nontargeting lentiviral shRNA constructs in the MD Anderson Vector Core.
UM-UC7 and UM-UC9 cells were incubated with or without 1 mM rosiglitazone
for 48 hr. Triplicate RNA isolates were prepared on different days for each
condition, and global changes in gene expression were determined by whole
genome expression profiling. The statistically significant changes in gene
expression were used to create signatures that were subsequently used in
the IPA and GSEA analyses presented in Figure 5.Statistical Analyses
Clinicodemographic characteristics were compared using Fisher’s exact
tests and Kruskal-Wallis tests to assess differences between groups in cate-
gorical and continuous variables, respectively. Kaplan-Meier analysis with
log-rank statistics was used to characterize survival distributions and associ-
ations between subtypes and survival outcomes. Statistical analysis was
performed using SPSS (version 19) and a p value less than 0.05 was consid-
ered significant.ACCESSION NUMBERS
The GEO accession numbers for the gene expression profiling data presented
in this study are GSE48277 and GSE47993.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and eleven tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2014.01.009.164 Cancer Cell 25, 152–165, February 10, 2014 ª2014 Elsevier Inc.ACKNOWLEDGMENTS
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